AbbVie Partners with Neomorph to Advance Oncology and Immunology Treatments

  • AbbVie and Neomorph, Inc. announced a collaboration to develop molecular glue degraders for oncology and immunology.
  • The deal includes up to $1.64 billion in option fees and milestones, alongside royalties on net sales.

AbbVie has entered into a collaboration and option-to-license agreement with Neomorph, Inc. to advance the development of molecular glue degraders for oncology and immunology. The partnership aims to tackle challenging and historically “undruggable” protein targets by leveraging molecular glue degraders—a new class of small molecules designed to trigger selective protein degradation.

The agreement will provide Neomorph with an upfront payment from AbbVie, along with potential milestone and option fees totalling up to $1.64 billion. Additionally, Neomorph is eligible for tiered royalties on net sales of any resulting products.

Steven Elmore, Vice President of Small Molecule Therapeutics and Platform Technologies at AbbVie, commented, “Protein degraders represent a groundbreaking advancement in the field of drug discovery, and at AbbVie we are committed to advancing this technology forward. We are excited to collaborate with Neomorph to develop novel molecular glue degraders which could pave the way for new, effective therapies in the treatment of immune disorders and cancer.”

Neomorph’s molecular glue platform has been developed over several years to provide broad coverage of the proteome. Phil Chamberlain, Co-Founder, President, and CEO of Neomorph, highlighted the potential of the partnership: “We are thrilled to partner with AbbVie, a global leader in delivering transformative medicines in oncology and immunology, as we aim to tackle some of the most challenging and valuable targets known.”

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.